Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world prospective study of apatinib in advanced non-central lung squamous cell carcinoma
ChiCTR-OPC-17012473Phase 4Recruiting
- Sponsor
- Yibin Second People's Hospital
- Start
- Oct 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in Pulmonary squamous cell carcinoma, sponsored by Yibin Second People's Hospital. Primary endpoints: Progression-free survival and Safety. Started Oct 2017; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR-OPC-17012473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17012473.